[go: up one dir, main page]

DK1294892T3 - Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) - Google Patents

Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)

Info

Publication number
DK1294892T3
DK1294892T3 DK01946643T DK01946643T DK1294892T3 DK 1294892 T3 DK1294892 T3 DK 1294892T3 DK 01946643 T DK01946643 T DK 01946643T DK 01946643 T DK01946643 T DK 01946643T DK 1294892 T3 DK1294892 T3 DK 1294892T3
Authority
DK
Denmark
Prior art keywords
vlps
influenza virus
particles
wild
aggregation
Prior art date
Application number
DK01946643T
Other languages
Danish (da)
English (en)
Inventor
Jose M Galarza
Theresa E Latham
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1294892T3 publication Critical patent/DK1294892T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01946643T 2000-06-23 2001-06-21 Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) DK1294892T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21365600P 2000-06-23 2000-06-23
US28441101P 2001-04-17 2001-04-17
PCT/US2001/019890 WO2002000885A2 (fr) 2000-06-23 2001-06-21 Assemblage sauvage-chimerique de particules viraloïdes de la grippe (vlp)

Publications (1)

Publication Number Publication Date
DK1294892T3 true DK1294892T3 (da) 2008-01-28

Family

ID=26908276

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01946643T DK1294892T3 (da) 2000-06-23 2001-06-21 Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)

Country Status (17)

Country Link
US (2) US7556940B2 (fr)
EP (1) EP1294892B1 (fr)
JP (1) JP5008244B2 (fr)
KR (1) KR100877019B1 (fr)
CN (1) CN1196788C (fr)
AT (1) ATE376059T1 (fr)
AU (2) AU2001268662A1 (fr)
BR (1) BRPI0111830B8 (fr)
CA (1) CA2410297C (fr)
CY (1) CY1107835T1 (fr)
DE (1) DE60130987T2 (fr)
DK (1) DK1294892T3 (fr)
ES (1) ES2295175T3 (fr)
IL (1) IL153290A0 (fr)
MX (1) MXPA02012254A (fr)
PT (1) PT1294892E (fr)
WO (1) WO2002000885A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0250488A (ja) * 1988-08-11 1990-02-20 Nec Corp 超伝導配線
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
EP1534344A4 (fr) * 2002-06-26 2008-05-28 Advanced Bionutrition Corp Virus et particules pseudovirales pour presentation multiple d'antigenes et de cibles
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
CN1833030B (zh) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 用于表达、传递及纯化目标多肽的重组载体分子
AU2011218606B2 (en) * 2003-07-11 2012-01-12 Novavax, Inc Functional influenza virus-like particles (VLPS)
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8551756B2 (en) * 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1766034B1 (fr) * 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le virus influenza
CA2597928A1 (fr) * 2005-02-16 2006-08-24 Lentigen Corporation Vecteurs lentiviraux et leurs utilisations
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
BRPI0614475B8 (pt) 2005-08-03 2021-05-25 Fraunhofer Usa Inc polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
AU2006304640B2 (en) * 2005-10-18 2012-10-11 Novavax, Inc. Functional influenza virus like particles (VLPs)
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
ATE552846T1 (de) 2005-12-06 2012-04-15 Yeda Res & Dev Verbesserter grippeimpfstoff
JP5198290B2 (ja) * 2006-02-02 2013-05-15 グローブイミューン,インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
AU2007215080A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126788A2 (fr) * 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthodes et compositions pour le traitement et la prévention d'une infection virale
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
WO2007130327A2 (fr) * 2006-05-01 2007-11-15 Technovax, Inc. Compositions de particules de type viral (vlp) de la grippe
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
WO2007144886A2 (fr) 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Particules de type viral destinées au traitement d'infections virales
US20100184832A1 (en) 2006-07-14 2010-07-22 Sanofi Pasteur Biologics Co. Construction of Recombinant Virus Vaccines by Direct Transposon-Mediated Insertion of Foreign Immunologic Determinants into Vector Virus Proteins
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2044224A4 (fr) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Particules de type virus chimérique
US20100239605A1 (en) * 2006-09-29 2010-09-23 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
WO2008058396A1 (fr) * 2006-11-15 2008-05-22 Folia Biotech Inc. Vaccins contre la grippe à base du virus de la mosaïque du papayer
AU2007330494B2 (en) * 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
WO2008148104A1 (fr) 2007-05-25 2008-12-04 Novavax, Inc. Nouvelles vlp dérivées de cellules qui n'expriment pas une matrice virale ou une protéine du noyau
CA2692933C (fr) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Antigenes yersinia pestis, compositions de vaccins, et methodes associees
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
CA2742288A1 (fr) * 2008-07-30 2010-02-04 Folia Biotech Inc. Vaccins multivalents a base du virus mosaique de la papaye et leurs utilisations
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2010243489A1 (en) * 2009-05-01 2011-12-22 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
EP2427547A1 (fr) * 2009-05-08 2012-03-14 GlaxoSmithKline Biologicals S.A. Méthode d'élaboration d'un virus à partir de culture de cellules mettant en uvre une homogénéisation
PL222497B1 (pl) * 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
CA2766899C (fr) 2009-07-02 2021-05-04 Massachusetts Institute Of Technology Compositions et procedes de diagnostic et/ou de traitement d'une infection grippale
WO2011041391A1 (fr) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Anticorps dirigés contre l'hémagglutinine du virus de la grippe, compositions, et procédés associés
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
WO2011056899A2 (fr) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
AU2010343095B2 (en) * 2009-12-28 2017-01-05 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
EP2519539A4 (fr) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc Procédés pour stabiliser des solutions de particules, semblables à des virus, à base de virus enveloppés d'un antigène de la grippe
US9352031B2 (en) 2010-02-18 2016-05-31 Technovax, Inc. Universal virus-like particle (VLP) influenza vaccines
CN102370976B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪口蹄疫病毒的混合病毒样颗粒、制备方法和应用
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
CN102373182A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
CN102373181B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪蓝耳病病毒混合病毒样颗粒、制备方法和应用
CN102373183A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和新城疫混合病毒样颗粒、制备方法和应用
CA2811023A1 (fr) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Traitement et/ou caracterisation de la grippe; polypeptides ha adaptes_a l'homme
BR112013007946B1 (pt) 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2828068C (fr) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Polypeptides multimeres multi-epitopes utilises dans des vaccins contre la grippe saisonniere et pandemique
KR20140047069A (ko) * 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원
WO2013019800A1 (fr) * 2011-08-01 2013-02-07 Emory University Ligands contenant vlps et leurs procédés associés
ES2953393T3 (es) * 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
WO2013142329A1 (fr) 2012-03-22 2013-09-26 Fraunhofer Usa, Inc. Particules de type virus comprenant une matrice de protéine à partir d'un virus enveloppé de plante et utilisations de celles-ci
BR112014023900A2 (pt) 2012-03-30 2020-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polipeptídeo de hemaglutimina de influenza recombinante, molécula de ácido nucleicoisolada, vetor, célula isolada, partícula semelhante ao vírus da influenza, proteína de fusão, composição, e uso
TWI434933B (zh) * 2012-04-17 2014-04-21 Nat Univ Tsing Hua 抗多型禽流感病毒之dna疫苗及其組合物
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
AU2013352179B2 (en) * 2012-11-27 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
EP2934581B1 (fr) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
KR101729387B1 (ko) 2015-04-17 2017-04-21 경희대학교 산학협력단 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 m1-m2-na-ha 바이러스 유사 입자의 제조방법
WO2017041100A2 (fr) 2015-09-03 2017-03-09 Novavax, Inc. Compositions vaccinales ayant une stabilité et une immunogénicité améliorées
US10391163B2 (en) * 2015-09-10 2019-08-27 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
EP3471767A4 (fr) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Hémagglutinines du virus de la grippe et utilisations de celles-ci
CN110325202B (zh) * 2016-10-31 2023-10-31 佐治亚州立大学研究基金会公司 乙型肝炎病毒pre-S蛋白的病毒样颗粒
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
EP3810634A4 (fr) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Polypeptides d'hémagglutinines du virus de la grippe en mosaïque et leurs utilisations
WO2020051766A1 (fr) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3956349A1 (fr) 2019-04-17 2022-02-23 The Broad Institute, Inc. Éditeurs de base d'adénine présentant des effets hors cible réduits
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
WO2022020800A2 (fr) 2020-07-24 2022-01-27 The General Hospital Corporation Pseudo-particules virales améliorées et leurs méthodes d'utilisation pour l'administration à des cellules
CN116063409A (zh) * 2022-09-09 2023-05-05 中山大学·深圳 一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5298244A (en) 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
ATE368729T1 (de) * 1999-04-06 2007-08-15 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.

Also Published As

Publication number Publication date
US8859231B2 (en) 2014-10-14
PT1294892E (pt) 2008-01-16
ES2295175T3 (es) 2008-04-16
AU2007201727A1 (en) 2007-05-10
ATE376059T1 (de) 2007-11-15
MXPA02012254A (es) 2003-04-25
IL153290A0 (en) 2003-07-06
DE60130987D1 (de) 2007-11-29
US20090239261A1 (en) 2009-09-24
DE60130987T2 (de) 2008-07-24
JP5008244B2 (ja) 2012-08-22
US7556940B2 (en) 2009-07-07
CY1107835T1 (el) 2013-06-19
US20050186621A1 (en) 2005-08-25
WO2002000885A2 (fr) 2002-01-03
BR0111830B1 (pt) 2014-12-02
KR20030013463A (ko) 2003-02-14
WO2002000885A3 (fr) 2002-08-08
EP1294892B1 (fr) 2007-10-17
CN1196788C (zh) 2005-04-13
CN1437655A (zh) 2003-08-20
CA2410297A1 (fr) 2002-01-03
AU2007201727B2 (en) 2009-06-04
EP1294892A2 (fr) 2003-03-26
KR100877019B1 (ko) 2009-01-07
BR0111830A (pt) 2003-03-25
CA2410297C (fr) 2011-03-15
WO2002000885A9 (fr) 2002-05-10
AU2001268662A1 (en) 2002-01-08
BRPI0111830B8 (pt) 2021-05-25
JP2004501647A (ja) 2004-01-22

Similar Documents

Publication Publication Date Title
DK1294892T3 (da) Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
MXPA96005662A (es) Vacunas de papilomavirus.
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
ES2263405T1 (es) Produccion de proteinas capsidas y particulas tipo virus de papilomavirus humano.
WO2005055957A3 (fr) Immunogene et vaccin contre la grippe
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
DK0677114T3 (da) Rekombinant svinekoppevirus
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
WO2004004761A3 (fr) Particule virale d'adjuvant
DE60138014D1 (de) Chimäre arterivirus-ähnliche partikel
WO2002000169A3 (fr) Production de vaccins par utilisation de plantes transgeniques ou de virus de plantes modifies comme vecteurs d'expression et proteines de coque virales transencapsidees utilisees comme systemes de presentation d'epitopes
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
DK1159968T3 (da) Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
ATE418997T1 (de) Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
ATE455124T1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
BRPI0411099A (pt) composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE69930960D1 (de) Synthetische virus-ähnliche partikel mit heterologen epitopen.
DE69728447D1 (de) Veränderte, kleine rna-viren
EP1309342A4 (fr) Production de papillomavirus humain chimerique